Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 9

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 9
---
 glaucoma, retinal vein occlusions, intraocular tumors, and
endophthalmitis. In addition, products and product candidates are being developed and used to treat symptoms associated with an eye disease
known as geographic atrophy. Most of the medicines in these products and product candidates are administered via intravitreal injection.
Therefore, we believe as these products and product candidates gain commercial adoption, the number of annual intravitreal injections
should increase further and at an increased rate as compared to recent years.

Vitrectomy
is a surgical procedure undertaken by a specialist where the vitreous humor gel that fills the eye cavity is removed to provide better
access to the retina. This allows for a variety of repairs, including the removal of scar tissue, laser repair of retinal detachments
and treatment of macular holes. According to data from Definitive Health from 2023, U.S. surgeons perform about 420,000 vitrectomies
each year. The number is likely to continue to grow as eye care providers find more uses for vitrectomy.

Chronic
non-infectious uveitis affecting the posterior segment of the eye is an inflammatory disease that afflicts people of all ages, producing
swelling and destroying eye tissues, which can lead to severe vision loss and blindness. Based on internal estimates and information
published on the MedScape website (which was updated as of March 2023) that cites various ranges of prevalence of uveitis, we estimate
this disease affects approximately 100,000 people each year in the U.S. The standard of care treatment for this disease typically involves
the use of short-acting corticosteroids to reduce uveitic flares (such as TRIESENCE) followed by additional treatments of sustained release,
lower dose steroids to minimize the risk of further flares.

Competition

The pharmaceutical and pharmacy
industries are highly competitive. We compete against branded drug companies, generic drug companies, outsourcing facilities and compounding
pharmacies. We are smaller than some of our competitors, and we may lack the financial and other resources needed to develop, produce,
distribute, market and commercialize any of our branded products and proprietary formulations or compete for market share in these sectors.
The drug products available through branded and generic drug companies with which our products and formulations compete have been approved
for marketing and sale by the FDA and are required to be manufactured in facilities compliant with cGMP standards. Although we prepare
some